• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RISEDRONIC ACID Drug Record

  • Summary
  • Interactions
  • Claims
  • RISEDRONIC ACID chembl:CHEMBL923 Approved

    Alternate Names:

    ACTONEL
    M05BA07
    NE-58095
    RISEDRONIC ACID
    RISEDRONATE
    ACTONEL®
    ACIDUM RISEDRONICUM
    RIDRON
    RISEDRONATE SODIUM
    ACIDE RISÉDRONIQE
    ATELVIA®
    ACIDO RISEDRONICO
    RISEDRONSÄURE
    rxcui:73056
    chembl:CHEMBL923
    pubchem.compound:5245
    chemidplus:105462-24-6
    drugbank:00884

    Drug Info:

    FDA Approval 1998
    Drug Indications Bisphosphonates
    FDA Approval approved
    Drug Class small molecule
    Drug Indications antiosteoporotic agent
    Year of Approval 1998
    Drug Class bisphosphonates
    (3 More Sources)

    Publications:

    Coxon et al., 2005, Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo., Bone
    Dunford et al., 2001, Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates., J. Pharmacol. Exp. Ther.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Ortiz-Gómez et al., 2006, Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate., Eukaryotic Cell
    Russell et al., 2007, Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy., Ann. N. Y. Acad. Sci.
    Bergstrom et al., 2000, Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase., Arch. Biochem. Biophys.
    Gritzalis D et al., 2015, Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase., Bioorg Med Chem Lett
    Yokoyama T et al., 2015, Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase., J Med Chem
    Corral-Gudino L et al., 2006, -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone., Bone
    Mossetti et al., 2005, Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment., Bone
  • RISEDRONIC ACID   FDPS

    Interaction Score: 15.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name risedronate sodium, NE-58095,Actonel, Benet, Atelvia
    Novel drug target Established target
    Trial Name -

    PMIDs:
    16006204 11160603 11752352 16835450 18056045 10620343 25630225 26314394


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • RISEDRONIC ACID   TNFRSF11B

    Interaction Score: 6.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15777635


    Sources:
    NCI

  • RISEDRONIC ACID   IL1B

    Interaction Score: 0.84

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16257277


    Sources:
    PharmGKB

  • RISEDRONIC ACID   EHMT2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: RISEDRONATE

    • Version: 01-August-2011

    Alternate Names:
    RISEDRONATE Primary Drug Name

    Drug Info:
    Drug Class bisphosphonates
    Year of Approval 1998

    Publications:

  • TdgClinicalTrial: RISEDRONATE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiosteoporotic agent
    Drug Class small molecule
    FDA Approval approved

    Publications:

  • NCI: RISEDRONATE

    • Version: 14-September-2017

    Alternate Names:
    C1528 NCI drug code

    Drug Info:

    Publications:
    Mossetti et al., 2005, Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment., Bone

  • DTC: RISEDRONIC ACID

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL923 ChEMBL Drug ID

    Drug Info:

    Publications:
    Gritzalis D et al., 2015, Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase., Bioorg Med Chem Lett
    Yokoyama T et al., 2015, Protonation State and Hydration of Bisphosphonate Bound to Farnesyl Pyrophosphate Synthase., J Med Chem

  • PharmGKB: risedronate

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Corral-Gudino L et al., 2006, -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone., Bone

  • TTD: Risedronate

    • Version: 2020.06.01

    Alternate Names:
    D0PA5S TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL923

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21